ArticleCancer2022

Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).

Hongsik Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.